NCT05979857View on ClinicalTrials.gov

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

August 15, 2025

Study Completion Date

August 15, 2027

Conditions
Lymphoma, Non-Hodgkin's, Adult
Interventions
DRUG

SP-3164

SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'

All Listed Sponsors
lead

Salarius Pharmaceuticals, LLC

INDUSTRY

NCT05979857 - Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter